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Chinese Herbal Medicine for Dysfunctional Uterine Bleeding:
a Meta-analysis
Xiang Tu, Gaomin Huang and Shengkui Tan
College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan
Province, China
We conducted a systematic review to evaluate the efficacy and safety of Chinese herbal
medicine (CHM) for dysfunctional uterine bleeding (DUB) by performing a meta-analysis.
Randomized controlled trials (RCTs) or quasi-RCTs comparing CHM vs no treatment,
placebo, conventional western medicine (CWM), or general non-specific surgical treatment for
DUB were identified by electronic and manual searches. Trials of CHM treatments with CWM
treatments were compared with CWM treatments alone. Jadad scale and allocation
concealment were used to assess the quality of included studies. Four RCTs or quasi-RCTs
involving 525 patients were included. The methodological quality was poor in all trials except
one trial. No serious adverse events were reported in the included studies. With the lack of trials
comparing CHM with no treatment or placebo, it is impossible to accurately evaluate the
efficacy of CHM. However, CHM in these studies seem to show an encouraging comparative
effectiveness with CWM. More RCTs with a higher quality are required.
Keywords: Chinese herbal medicine–dysfunctional uterine bleeding–meta-analysis–
randomized controlled trials–systematic review
Background
Dysfunctional uterine bleeding (DUB) is defined as
abnormal uterine bleeding without a demonstrable organic
cause (1). It is a commonly encountered gynecologic
disease. DUB occurs most commonly at the extremes
of reproductive age (20% of cases occur in adolescence and
40% in patients over age 40) (2). DUB can be divided into
ovulatory and anovulatory. In adolescent and perimeno-
pausal age groups, 90% of DUB is anovulatory (3).
The goals of treatment for DUB are to control acute
bleeding, avert future episodes of bleeding, prevent
serious long-term consequences of anovulation and
endometrial cancer (4). DUB can be treated medically
or surgically. Management depends on the age and needs
of the patient.
In China, due to the long co-existence of conventional
western medical hospitals and traditional Chinese medical
hospitals, people are usually exposed to a combination of
western and Chinese therapies. As the communication
between China and other countries around the world
becomes more interactive and the international policies
of herbal medicine are improved step by step, Chinese
herbal medicine (CHM) will become more and more
available throughout the world.
In TCM basic theory, Kidney-Qi is composed of
Kidney-yang and Kidney-yin. Kidney-yang warms and
promotes the growth of tissues and organs in the human
body. Kidney-yin moistens and nourishes the viscera,
tissues and organs. The balance of Yin and Yang in
Zang-Fu organs is the motive power for the formation of
Qi and Blood. Blood is the substantial basis of
menstruation and the circulation of blood and menstrua-
tion depends on the promotion of Qi. In TCM theory the
most important mechanism for the generation of
menstruation is the co-ordinative effect of Kidney-Qi,
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properly cited.Tiangui, thoroughfare, conception vessels (Chong
Channel and Ren meridian) and the uterus. The Tiangui
is a kind of substance necessary for promoting the
development and maturity of the gonad. This is
generated and derived from congenital essence and
strengthened by essence acquired after birth from food.
Tiangui begins to play its motivational role of generating
menstruation, while the thoroughfare (the sea of blood
and twelve meridians) and conception vessel (the sea of
Yin meridians) are strengthened by the Qi and blood of
Zang–Fu organs and adjusted by the governor
(Du Channel, the sea of Yang meridians) and belt vessels
(Dai Channel). The belt vessel restrains all the up-and-
down meridians and the normal physiologic excretions of
the uterus, accumulating Yin-Blood of the viscera under
the influence of Tiangui. Yin-Blood fills the sea of blood
over time, flows into the uterus and changes into
menstruation. In TCM, these cycles are the generating
mechanism of menstruation (Fig. 1).
According to clinical manifestations, DUB is similar to
other aspects of irregular menstruation such as metror-
rhagia, metrostasis and intermenstrual bleeding in
Traditional Chinese Medicine (TCM) (5). In TCM
theory, DUB is usually caused by the following: insuffi-
ciency of qi, blood heat, blood stasis due to insufficiency of
kidney-qi or kidney-yin, insufficiency of spleen, or weak-
ness of the thoroughfare and conception vessels.
The therapeutic methods vary according to different
manifestations. Three therapeutic principles most often
used to treat metrorrhagia and metrostasis are: to stop
bleeding, determine the cause and deal with the principal
aspect and most importantly, restore normal
menstruation.
Rats injected with androgen became anovulia. Chinese
herbal medicinal compound prescriptions were given to the
rats which increased the weight of the ovaries and uterus
and thickened the endometria. The herbal compounds
could also increase the quantity of glands in the
endometrium, folliculi and corpus luteum and make the
interstitial glands to become prosperous (6). The herbal
compounds can also ameliorate the morphosis of the
adenohypophysis and adjust the endocrine function of the
adenohypophysis. Hence, they can promote ovarian follicle
growth, corpus luteum formation and ovulation (7).
CHM has been widely used to treat DUB in China and
many clinical trials have been conducted to investigate
their efficacy. These trials, however, could not provide
evidence because of the poor quality of their methodol-
ogy. Thus, it is necessary to assess CHM in terms of no
treatment or placebo and also to compare CHM with
conventional western medicine (CWM). Furthermore,
it should be determined by systematic review whether
CHM offers any advantage when combined with
conventional western therapies for the treatment of DUB.
Methods
Truly or quasi-randomized controlled trials (RCTs)
of CHM for DUB were included, regardless of whether
the intervention was blinded to patients, clinicians or
researchers after randomization was done. Trials that
compared CWM with CHM in the control arm were also
included. Trials using animals or their processed products
were excluded. To keep the integrity of TCM, processed
products from minerals and animal excretions were
permitted to be used as adjunct drugs in this review.
All eligible literature was included regardless of language.
In accordance with our main purpose outlined above, the
trials that used CHM in both the treatment and control
groups were excluded, as well as the trials that did
not report diagnostic criteria.
Participants
DUB diagnosis was based on ruling out organic causes
classified into three categories: pelvic pathology, systemic
diseases and iatrogenic causes for abnormal bleeding
(excluding pregnancy) (8). Only patients with histories,
clinical symptoms, physical examinations and supplemen-
tary test data that showed no organic disorder with any
type of DUB were eligible. Patients suffering from bleeding
due to pregnancy, use of an intrauterine contraceptive



















Figure 1. Generating mechanism of menstruation in TCM.
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Experimental treatment included CHM (different agents,
doses and routes of administration). Control treatment
included no intervention, placebo, CWM or general non-
specific surgery. The treatment group received CHM in
conjunction with western medical treatment. The control
group received the same western medical treatment with
no adjunct therapies. Three conventional western medical
treatments were used. The first treatment included a
treatment for anemia secondary to DUB, the second was
a hemostat agent treatment and the third was hormonal
therapy. General non-specific surgery was defined as
dilatation and curettage (D&C), hysterectomy and
endometrial ablation.
Outcome Measures
Considering that the outcome measures of most TCM
studies are based on clinical research guidelines invented
by the Chinese State Administration of TCM, six main
outcomes were considered:
ðiÞ Total effect rate
¼
Number of cases where symptoms improvement
Total number of cases that received treatment
ðiiÞ Normalization rate of menstruation
¼
Number of cases with normal menstruation over three
menstrual cyclesþNumber of cases with menopause
Total number of cases that received treatment
(normal menstruation mainly referred to menstrual cycle,
menstrual period, menstruation volume)
ðiiiÞ Hemostasis rate
¼
Number of cases that stopped bleeding in ten days
ðincluding the tenth dayÞ
Total number of cases that received treatment
(iv) The amount of menstrual blood loss.
ðvÞ Recurrence rate
¼
Number of cases where symptoms reoccurred within six
months after treatment
Total number of cases that showed positive responses to
the treatment with follow up
(vi) Adverse effects during treatment period that were
recorded.
Search Strategy for Identification of Studies
Following databases were searched for relevant studies:
PubMed, CBM disk (Chinese Biomedical Disk), CJFD
(Chinese Journal Full-text Database), DOC
FT
(Dissertation of China, full-text), CSTJ (Chinese Scientific
and Technological Journals Database). Every database
was searched from its starting date to 2006 in Chinese
and English. The search strategy on CBM disk is
illustrated in Table 1. Thirty-two Chinese professional
journals were manually searched (Table 2).
Data Collection
Data were collected independently by two reviewers.
Reviewers should solve discrepancies between them by
discussion if some discrepancies exist. If they were unable
to solve the disagreement through discussion, authors
were contacted to clarify the details.
Quality Assessment
Jadad scale and allocation concealment were used to
score the quality of the included studies. Based on scores,
we broadly subdivided them into the following two
categories: the total score is 5; those scoring below 3
classified as low quality and 3–5 as high quality.
Allocation concealment was assessed according to
Revman 4.2.7 User Guide. A, B, C, D was used to
indicate the quality of concealment: A indicates adequate
Table 1. Search strategy on CBM disk
1 Explode ‘Functional Uterine Bleeding’/all subheadings
2 Dysfunctional Uterine Bleeding
3 1 OR 2
4 Explode ‘Drugs, Chinese Herbal’/all subheadings
5 Chinese Herbal Drugs
6 Medicinal Herbs
7 Traditional Chinese Medicine
8 4 OR 5 OR 6 OR 7
9 3 AND 8
Table 2. Hand searching Chinese professional journals (1980.1–2006.1)
Acta Chinese Medicine and Pharmacology; Beijing Journal of
Traditional Chinese Medicine; Chinese Journal of Basic Medicine in
Traditional Chinese Medicine; Chinese Journal of integrated traditional
and western medicine; Chinese Traditional and Herbal Drugs; Chinese
Traditional Patent Medicine; China Journal of Chinese Materia
Medica; Chinese Journal of Information on Traditional Chinese
Medicine; Chinese Journal of Obstetrics and Gynecology; Chinese
Journal of Traditional Medical Science And Technology; Forum on
Traditional Chinese Medicine; Fujian Journal of Traditional Chinese
Medicine; Guangming Journal of Chinese Medicine; Hubei Journal of
Traditional Chinese Medicine; Heilongjiang Journal of Traditional
Chinese Medicine; International Journal of Traditional Chinese
Medicine; Journal of Beijing University of Traditional Chinese
Medicine; Journal of Traditional Chinese Medicine University of
Hunan; Journal of Shanxi College of Traditional Chinese Medicine;
Journal of Emergency in Traditional Chinese Medicine; Jiangsu Journal
of Traditional Chinese Medicine; Journal of Gansu college of
Traditional Chinese Medicine; Journal of Traditional Chinese Medicinal
Literature; Journal of Traditional Chinese Medicine; Journal of Nanjing
University of Traditional Chinese Medicine; Jilin Journal of Traditional
Chinese Medicine; New Journal of Traditional Chinese Medicine;
Shandong Journal of Traditional Chinese Medicine; Shanghai Journal
of Traditional Chinese Medicine; Shanxi Journal of Traditional Chinese
Medicine; Traditional Chinese Medicinal Research; Zhejiang Journal
of Traditional Chinese Medicine.
eCAM 2009;6(1) 101concealment of the allocation; B indicates uncertainty
that concealment was adequate; C indicates inadequate
concealment; D indicates the score was not assigned (9).
Data Analysis
Data were analyzed using Revman 4.2.7 downloaded
from the website of Cochrane collaboration. Meta-
analysis was performed for the data. The dichotomous
data were expressed as odds ratio (OR) with correspond-
ing 95% confidence interval (95%CI). For continuous
data, weighted mean difference (WMD) and 95%CI were
calculated. Heterogeneity was tested by 
2 test.
The comparison (Tables 6–7) was split into two parts:
first comparing CHM with CWM and second, comparing
CHM plus CWM to CWM alone. Although the
constituents of the compounds were different in each
investigation, the whole compounds of CHM had to
exhibit some of the following benefits of nourishing
kidney and qi, strengthening spleen and clearing away
heat, or invigorate the thoroughfare and conception
vessels and stop bleeding. A process was designed to
combine across studies to perform a meta-analysis. If the
main effects of the whole compound in the studies were
similar, the data was combined. The fixed-effect mode
was used to combine dichotomous data if homogeneity
was found. If heterogeneity was found, the random effect
mode was alternatively used. To make the meta-analysis
more clinically meaningful, trials with different hormonal
therapies involving a combination with necessary hemo-
stat agent treatment for anemia secondary to DUB were
lumped together. In the treatment of DUB, if one kind of
hormone is not so effective, another kind of hormone
may be alternatively used. Publication bias would be
examined by the funnel plot.
Results
Four RCTs Met Inclusion Criteria
Four Chinese RCTs or quasi-RCTs (10–13) that met the
inclusion criteria were included (Table 3). The main
reasons for exclusion are as follows: (i) it was confirmed
that animals or processed animal products were used in
the TCM formulas, (ii) the treatment in the control group
was different from what was given to the treatment
group except CHM, (iii) trials had statistical errors and
(iv) trials that did not report diagnostic criteria definitely.
(v)Trials where is a big gap between the sample size of
the experimental group and the control group (experi-
mental group cases: control group cases 42:1). While
imbalanced random allocation was not mentioned in
these trials or (vi) those trials whose authors failed to
describe the randomization process correctly when they
were required to clarify details. (vii) As well as trials
whose author could not be contacted, (viii) trials not able
to obtain the full-text and (ix) trials used CHM both in
the treatment and control group.
Methodological Quality Varied From High to Low
Table 4 illustrates the quality of the trials with one
classified as high and the rest low. All claimed
‘randomization’. One author (13) provided additional
information that imbalanced random allocation inform-
ation (2:1) was used in his trial. One trial (12) randomly
allocated patients with random digit tables and
another trial (10) allocated patients by patients’ medical
record numbers. Details that patients were randomly
allocated by random digit tables in one trial (13) were
clarified thanks to the kindness of the author. No studies
mentioned the use of allocation concealment and
blindness. All trials gave baseline characteristics
in terms of age and duration of symptoms. One trial
(10) simply stated the baseline characteristics of all the











He (10) 18/17 Unclear Unclear Oral Tiaojing hao,
progesterone im
Progesterone im 3–6
Cheng (11) 42/42 14–above
40/14–above 40
4–33/5–36 Oral Bazhen Tang,
DES, MPA
Oral DES, MPA 3





Xie (13) 60/30 11–21/11–20 1–24/20d–24 Oral Fufang
ShuDi capsule
Oral DES, MPA 3
DES indicates diethylstilbestrol; MPA, medroxyprogesterone acetate.





He (10) Unclear 0 D
Cheng (11) Unclear 1 D
Du (12) Unclear 2 D
Xie (13) 6 3 D
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each group and claimed ‘no significant differences were
identified’ and two trials (11–13) reported the P-value
(P40.05). Information about withdrawal and failure to
follow-up was provided in only one trial (13). In (13) four
cases withdrew during treatment and two patients in the
control group failed to follow-up. Arrays of herbal
medicines were used in the four trials (Table 5).
Results of meta-analysis
We found no trials compared CHM with no treatment
or placebo.
CHM vs Conventional Medicine
Two studies compared CHM with CWM. Since they
nourished the kidneys and stopping bleeding, we com-
bined data across two studies (Table 6).
Notably, the meta-analysis of the high quality trial (13)
demonstrated that there was no significant difference in
normalization rate of menstruation.
CHM and Conventional Medicine vs Conventional
Medicine Alone
Two studies compared CHM and CWM vs CWM alone
in the treatment of DUB (Table 7). The compound in one
study is used to nourish qi and stop bleeding while the
other is only to stop bleeding. No serious adverse events
were reported. With fewer than five trials to compare, we
did not use a funnel plot to examine publication bias.
Discussion
The women’s ages ranged from 11 to 50 and the duration
of symptoms varied from 20 days to 120 months,
Table 5. The herbal medicines used in the trials
Trials Medicinal herbs used in the trials
He and Li, (10) Typha angustifolia Typhaceae, Trogopterus xanthipes Petauristidae, Prunella vulgaris Labiatae.
Cheng, (11) Angelica sinensis Umbelliferae, Ligusticum chuanxiong Umbelliferae, Rehmannia glutinosa Scrophulariaceae, Paeonia
lactiflora Ranunculaceae, Codonopsis pilosula Campanulaceae, Atractylodes macrocephala Compositae, Poria cocos
Polyporaceae, Glycyrrhiza uralensis Leguminosae, Lycium barbarum Solanaceae, Custuta chinensis Convolvulaceae, Rubus
chiagii Rosaceae, Polygonum multiflorum Polygonaceae.
Du et al., (12) Psoralea corylifolia Papilionaceae, Dipsacus asper Dipsacaceae, Codonopsis pilosula Campanulaceae, Cimicifuga
heracleifolia Ranunculaceae, Typha angustifolia Typhaceae, Rubia cordifloia Rubiaceae, Halloysite, Ligustrum lucidum
Oleaceae, Lycium barbarum Solanaceae, Angelica sinensis Umbelliferae, Paeonia lactiflora Ranunculaceae, Dioscorea
opposita Dioscoreaceae, Curculigo orchioides Amaryllidaceae, Custuta chinensis Convolvulaceae, Rubus chiagii Rosaceae,
Carthamus tinctorius Compositae.
Xie et al., (13) Rehmannia glutinosa Scrophulariaceae, Custuta chinensis Convolvulaceae, Coix lacryma-jobi ma-yuan Gramineae,
Dipsacus asper Dipsacaceae, Eclipta prostrata Compositae, Ligustrum lucidum Oleaceae, Epimedium brevicornum
Berberidaceae, Cornus officinalis Cornaceae, Dioscorea opposita Dioscoreaceae, Paeonia lactiflora Ranunculaceae,
Leonurus heterophyllus Labiatae, Typha angustifolia Typhaceae, Trogopterus xanthipes Petauristidae, Arnebia euchroma
Boraginaceae.
Table 6. Chinese herbal medicine vs conventional western medicine
Outcome measures Trials Participants Statistical method Odds ratio (95% CI) P-value
CHM group CWM group
Total effect rate
Du (12) 123/174 100/142 OR(fixed) 1.01(0.62,1.65)
Xie (13) 51/60 22/30 OR(fixed) 2.06(0.70,6.04)
Overall effect OR(fixed) 1.14(0.73,1.77) 0.57
Normalization rate of menstruation
Du (12) 40/174 16/142 OR(fixed) 2.35(1.25,4.41)
Xie (13) 18/60 9/30 OR(fixed) 1.00(0.38,2.60)
Overall effect OR(fixed) 1.83(1.09,3.09) 0.02
Hemostasis rate
Du (12) 170/174 136/142 OR(fixed) 1.88(0.52,6.78)
Xie (13) 51/60 22/30 OR(fixed) 2.06(0.70,6.04)
Overall effect OR(fixed) 1.98(0.87,4.52) 0.11
Recurrence rate
Xie (13) 3/31 9/17 OR(fixed) 0.10(0.02,0.44) 0.003
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scientifically described the severity of symptoms before
the patients entered the trials. Only 31 patients were
followed-up in (13), which makes it difficult to accurately
evaluate these terms.
We found only a few trials that compared CHM
with surgery. John Bonnar and Brian L Sheppard (14)
recommended that patients with DUB should be offered
effective drug treatment with tranexamic acid before
considering surgical treatment. Hysterectomies have been
the traditional surgical procedure used to treat menor-
rhagia secondary to DUB. The systematic review of
Neil Johnson and David Barlow et al. (15) found no
important disadvantages of vaginal hysterectomy com-
pared with other surgical approaches, such as avoiding
abdominal hysterectomy accelerates recovery, diminishes
post-operative pain and avoids abdominal wall infections
and general post-operative febrile illness. Laparoscopic
hysterectomy may help to avoid a laparotomy, but
urinary tract injury is a genuine concern.
Over the past 10 years there has been an international
upsurge of interest in decreasing hysterectomy rates in the
gynecologic community. Some less complicated methods
of endometrial ablation, like NovaSure system have been
developed and offer the gynecologist excellent alternatives
in the treatment of DUB so that hysterectomy can be
avoided (16). S. B. Pinion et al. (17) demonstrated that
hysteroscopic surgery could be recommended and
should be encouraged as an alternative for the majority
of women when more conservative treatment had failed.
Interestingly, hysteroscopic surgery and hysterectomy
have a similar effect on psychiatric and psychosocial
outcomes (18). Neither treatment affected marital rela-
tionships nor both treatments had a similar influence
on sexual relationships. Trials comparing CHM with
surgery should be conducted to comprehensively assess
the benefits of CHM in the treatment of DUB. Deciding
which treatment is best is complex. All these options
should be discussed with patients, considering the relative
advantages and disadvantages before making a decision
on treatment.
Herbal medicine, including Chinese herbs, is gaining
popularity as an alternative therapy all over the world.
For instance, spending on herbal products in the
United Kingdom is over £40m a year, mainly from self
prescription of over the counter products (19). Originally
confined to health food shops, herbal remedies are now
marketed in many conventional pharmacies. On the other
hand, there are still some hurdles, which are partly
caused by the lack of strong evidence from reputable
medical sources and this slows the spread of herbal
medicine. For example, in one review article, the author
stated that clinicians should prescribe or recommend
herbal remedies only if their use had been proved
effective by rigorous study and only a small fraction
of the thousands of medicinal plants used worldwide
have been tested rigorously in randomized, controlled
trials (20).
CHM for the treatment of DUB had different
outcomes. Some of the outcome measures regulated
by the authorities of TCM are quite specific and that is
what TCM clinical studies have to obey. The assessment
of menstrual loss may be based on the Chinese
participants’ views, but it is never evaluated scientifically
and rigidly. A standardized outcome index should be
developed to make assessment more scientific and
future investigations should adapt objective and quanti-
tative measurements. Few trials have observed the
amount of menstrual blood loss, ovulation in women
suffering from anovulatory DUB and their quality of life,
making it difficult to draw conclusions from these
outcomes.
No multi-center, large sample and co-operative studies
were found and there were many differences in sample
Table 7. Chinese herbal medicine plus conventional western medicine vs conventional western medicine
Outcome measures Sub-category Trials Participants Statistical method Odds ratio (95% CI) P value





Cheng (11) 41/42 33/42 OR(fixed) 11.18(1.35,92.81) 0.03
Chinese herbal medicine
stopping bleeding
He (10) 17/18 9/17 OR(fixed) 15.11(1.62,140.58) 0.02
Overall effect OR(fixed) 12.74(2.72,59.72) 0.001




Cheng (11) 32/42 12/42 OR(fixed) 8.00(3.01,21.23) 50.0001
Chinese herbal medicine
stopping bleeding
He (10) 8/18 2/17 OR(fixed) 6.00(1.05,34.32) 0.04
Overall effect OR(fixed) 7.43(3.16,17.44) 50.00001
104 Efficacy and safety of Chinese herbal medicine for DUBsize between treatment groups and control groups in
some randomized trials, which were beyond the range of
randomized allocation. No trials estimated the sample
size. None were strong enough to state conclusively
whether there were differences between CHM and other
treatments. Although all trials claimed randomization,
they failed to provide enough information to judge
whether the randomization procedures had been carried
out properly. Gynecologists should pay more attention
to the safety of CHM for DUB.
The prevalence of poor quality studies calls to TCM
clinicians and scientists to improve the quality of TCM
investigations not only in gynecologic areas but in all
clinical fields.
Conclusion
The results of meta-analysis of clinical practice demon-
strated that CHM used under the guidelines of basic
TCM theory gained encouraging results in the treatment
of DUB, especially when combined with western
medicine. Most women in the included trials stopped
bleeding and many of them regained normal menstrua-
tion in a certain period of time. No adverse events were
reported due to (in part) the use of herbs which are
mostly not noxious with few side effects. A great deal
of emphasis was placed on treatment based on differ-
entiation. Modification of corresponding assistant and
adjunctive herbs in formulas according to the accom-
panying symptoms is very common in these studies.
Lumping trials of herbal compounds with the same or
similar effects together had not caused heterogeneity,
which, perhaps, is a prospective method for TCM
formulas varying widely in constituents when performing
meta-analysis.
Due to the lack of trials comparing CHM with no
treatment or placebo, it is impossible to evaluate the
effectiveness of CHM. CHM treatment in these studies
seems to show a favorable comparative effect on the
control of western medicine. However, the poor metho-
dological quality may weaken the validity of the results.
Owing to the lack of RCTs with high methodologic
quality, we have to wait. In this case, the waiting period
could be a time to develop hypotheses to explain the
results that have been achieved in individuals and
trials conducted lower on the golden pyramid (21).
Performing clinical trials with high methodological
quality of TCM for DUB is very helpful to accurately
assess the benefits and potential risks in the treatment of
DUB. In the future, more rigorously designed, rando-
mized, double-blind, placebo-controlled trials with large
sample size are needed to make TCM accepted by more
people in the world.
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